NewAmsterdam Pharma (NASDAQ:NAMS) Stock Price & Analysis

$22.80

USD

+0.94(4.30%)

At close: Sep 11, 18:37 EDT

Open

$35.825

Prev. Close

$21.86

High

$35.825

Low

$33.83

Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

CEOMichael Harvey Davidson Facp.

SectorHealthcare

IndustryBiotechnology

Employees

Recently from Cashu

100

IPO DateFeb 9, 2021

ExchangeNASDAQ

Exchange NameNASDAQ

CurrencyUSD

Headquarters & Contact

AddressGooimeer 2-35

City / State / ZIPNaarden, NH, 1411 DC

CountryNetherlands

Phone31 35 206 2971

Websitehttps://www.newamsterdampharma.com